



11 May 2021

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2021.

Adoption of income statement and balance sheet for the financial year 2020 and discharge from liability

The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the board of directors and the managing director were discharged from liability for the financial year 2020.

Allocation of profit or loss

The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2020 and that the results of the company shall be carried forward.

Election of board members and auditors, and fees to the board of directors and auditors

The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Jacob Gunterberg, Heidi Hunter, Maarten Kraan, Sara Malcus, Hans Schikan and Michael Wolff Jensen as members of the board of directors for the period until the end of the next annual general meeting. Michael Wolff Jensen was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting.

The AGM further resolved on directors’ fees in accordance with the nomination committee’s proposal. The AGM further resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor shall be paid as per approved statement of costs.

Nomination committee for the next annual general meeting

The AGM resolved, in accordance with the nomination committee’s proposal, on principles for appointing the nomination committee. In short, the principles imply that the nomination committee should be composed of the chairman of the board of directors together with one representative of each of the three largest shareholders in terms of votes, based on ownership in the company as of 31 August.

Guidelines on remuneration to group management

The AGM resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to group management. In short, the guidelines state that remuneration within Vicore Pharma shall be based on principles of performance, competitiveness and fairness and consist of fixed



remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits.

Approval of the board of directors' remuneration report

The AGM resolved to approve the remuneration report presented by the board of directors.

Authorization to issue new shares

The authorization to issue new shares was not approved by the AGM.

Introduction of a long-term performance-based incentive program for certain members of the Board of Directors

The AGM resolved in accordance with the nomination committee's proposal to implement a long-term performance-based incentive program for certain members of the Board of Directors, comprising not more than 73,000 share awards. It was further resolved, in accordance with the nomination committee's proposal, to issue not more than 73,000 warrants in order to, at the end of the program, ensure delivery of shares to the participants.

Introduction of a long-term incentive program for the company's senior management and key persons

The AGM resolved in accordance with the board of directors' proposal to implement a long-term incentive program for the senior management and key persons based on yearly grants of options. The total number of options that may be allocated to the participants amounts to not more than 3,000,000. It was further resolved, in accordance with the board of directors' proposal, to issue not more than 3,000,000 warrants in order to ensure delivery of shares to the participants as well as, if necessary, related security costs.

Amendment of the articles of association

The AGM resolved in accordance with the board of directors' proposal to amend the articles of association so that the limits for the company's share capital and number of shares are changed.

Gothenburg, 11 May 2021

Vicore Pharma Holding AB (publ)

For further information, please contact:

Carl-Johan Dalsgaard, CEO

Phone: +46 70 975 98 63

E-mail: carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO

Phone: +46 70 553 14 65

E-mail: hans.jeppsson@vicorepharma.com



The information was submitted for publication, through the agency of the contact persons set out above, on 11 May 2021 at 11:30 CEST.

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a rare disease pharmaceutical company focused on fibrotic lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.